SHANGHAI, Dec. 30, 2025 — Mabwell (688062.SH), a biopharmaceutical company driven by innovation and having a fully integrated industry chain, announced that the Phase II clinical trial of its self-developed innovative anti-IL-11 monoclonal antibody (R&D code: 9MW3811) for pathological scarring recently finished the first patient dosing in China, becoming the world’s first drug candidate targeting IL-11 to start clinical trials for pathological scarring.

This Phase II clinical trial (CTR20254857) is intended to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring. The first patient received the dose at the Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine. Previously, 9MW3811 had completed Phase I trials on healthy subjects in Australia and China, and the results showed a good safety profile and a half-life of over one month.

Interleukin-11 (IL-11) is a cytokine that plays a crucial role in chronic inflammation and fibrosis-related diseases and is widely involved in the fibrosis process of multiple organs. Preclinical research indicates that 9MW3811 has shown significant efficacy in various models like pulmonary fibrosis and has demonstrated potential application value in fibrosis-related diseases such as hypertrophic scar and abnormal endometrial bleeding. Especially in human-derived keloid animal models, 9MW3811 can effectively relieve the skin fibrosis process and reduce the volume of existing scars. Currently, there is a shortage of effective therapeutic drugs for hypertrophic scars and keloids, suggesting significant unmet clinical needs. 9MW3811 is expected to bring new treatment options to patients.

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities covering the entire pharmaceutical value chain. The company is dedicated to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit .

Forward-Looking Statements

This press release includes forward-looking statements which include, but are not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those related to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are of a predictive nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may lead to actual results being materially different from any future results expressed or implied in the forward-looking statements. These statements can be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: the environment; politics; the economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete the required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties worsen, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company warns all persons not to place excessive reliance on any such forward-looking statements, which are only valid as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release apply to this statement.

SOURCE Mabwell